Adding Botulinum Toxin to Celiac Plexus Block Improves Pain Response

A retrospective single-center study compared celiac plexus block alone versus celiac plexus block plus botulinum toxin type A in 60 patients with pancreatic cancer pain. The study reported significantly higher positive responder rates at 4 weeks with the botulinum toxin combination (65.4% vs 8.8%), along with lower pain scores, fewer rescue interventions, and longer duration of analgesic response through 12 weeks; botulinum toxin use was independently associated with treatment success in multivariable analysis. The authors state findings warrant further prospective validation.

Most relevant for: Patients with pancreatic cancer experiencing pain managed with celiac plexus block.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.